A scientific workflow for hantavirus therapeutic evidence.
A transparent modelling narrative can connect antiviral assay signal, potency, human exposure, mechanistic viral dynamics, and virtual population outcomes. The emphasis is on how each evidence layer informs the next, what each model contributes, and where uncertainty remains.
Each stage answers a different scientific question.
The workflow is intentionally staged. Early assay data identify signal; potency models quantify the signal; PK translation asks whether the signal is reachable in humans; mechanistic PK/PD and virtual populations test whether the exposure-response relationship could plausibly alter infection trajectories.
Inspect the outputs by evidence type.
The plots are kept as primary scientific objects. The surrounding text focuses on what each figure establishes, what decision it informs, and what should still be tested experimentally or clinically.
Viral modelling links exposure to infection dynamics.
The schematic at the top of the page shows the central scientific idea: drug exposure is translated into a change in viral processes, and those process-level changes are propagated into viral-load trajectories and population outcomes. The model basis is therefore not a single curve, but a linked representation of pharmacology, viral replication, and between-subject variability.
How to read these simulations.
The value of this type of analysis is in connecting biological mechanism to quantitative decision points. A compound is not advanced simply because it shows assay activity; it must also have an interpretable potency profile, plausible human exposure, and a mechanism that can produce meaningful changes in viral kinetics.
- Assay activity is treated as a starting point, not as proof of clinical relevance.
- Potency parameters become translational targets only when interpreted alongside human exposure.
- Mechanistic viral dynamics help distinguish suppression, delayed clearance, and rebound patterns.
- Population simulations make uncertainty and between-subject variability visible.
Scientific guardrails
Evidence status: These figures illustrate model behaviour under defined example scenarios. They are suitable for discussing workflow structure, model interpretation, and translational questions, but not for asserting real-world efficacy.
Next evidence needs: compound identity, cytotoxicity, selectivity index, protein binding, human PK constraints, assay system details, strain relevance, and any observed longitudinal viral-load data.
Decision value: The framework is most useful when it narrows a broad hit list into candidates or combinations with plausible human exposure-response support.
Expert perspective on translational prioritisation
Dr Shaun Pennington, who helped lead SARS-CoV-2 therapeutic screening activities at the Liverpool School of Tropical Medicine during the COVID-19 pandemic, commented:
“One of the key lessons from COVID-19 was that speed matters, but so does biological and pharmacological context. Screening compounds for antiviral activity is only part of the picture. The most useful approaches are those that combine preclinical efficacy data with what is already known about human pharmacokinetics, exposure, safety and dosing feasibility. For emerging threats such as hantaviruses, this type of integrated analysis could help identify repurposed candidates that are not only active in experimental systems, but also have a plausible route towards clinical impact.”
